

CASE STUDY

# Six-Year Collaboration Across Six Indications for Groundbreaking Oncology Therapy

---


Evidera's Evidence  
Synthesis, Modeling &  
Communication team can  
transform your evidence  
into value

**100+**

large pharmaceutical clients  
supported in the past five years

**130+**

HTA submissions in the  
past five years



## Key Takeaways

Generated integrated packages of evidence for oncology drug, including value messaging, systematic reviews and comparative effectiveness analyses, and economic models, for 18+ country submissions across six indications

---

Earned our client's trust as a strategic partner

## Background

A large pharmaceutical client developed an innovative, targeted therapy for the treatment of several blood cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenstrom macroglobulinemia (WM). This targeted therapy provided game-changing benefits, such as dramatic improvements to progression-free survival, overall survival, and improved toxicity profiles compared to chemotherapy, versus standard of care. The client required a strong value story, comparative evidence, and economic value demonstration to justify pricing and address incumbents downstream.

## Approach

Our Evidence Synthesis, Modeling & Communication team generated integrated packages of evidence, including value messaging, systematic reviews and comparative effectiveness analyses, and economic models for six indications. Additionally, we tailored evidence synthesis and economic models to local contexts and supported global and EMEA-specific strategy development for successful HTA submissions.

## Results

In the span of two years, our team developed global evidence packages for four indications and supported multiple successful HTA submissions. Because of this, we earned our client's trust as a strategic partner – a relationship that continues to this day and has led to continuous follow-on work.

## Impact

- 18+ country submissions across six indications for oncology drug
- Published two manuscripts and 10+ abstracts and posters summarizing our research and communicating the therapy's value
- Adaptations to 18+ countries across six indications, including positive NICE, NCPE, SMC, and HAS recommendations



**Unified body of evidence** provides overall impact and probability of **successful submission**



**Deep relationships with stakeholders** across the industry

---

*Our multi-disciplinary team of more than 180 scientific and clinical experts provides a holistic approach to HEOR studies to understand and adapt to your needs. We leverage our diverse set of industry-leading experts across evidence synthesis, modeling and simulation, and market access communications to provide end-to-end support and guidance across projects.*

[Learn more at evidera.com/what-we-do/emc/](https://evidera.com/what-we-do/emc/)